Intervention

PLX3397

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting1

Common conditions19

Lead sponsors shown4

Clinical trials

5 shown

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerNCT01042379 · 2010-03-01

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsNCT02452424 · 2015-07-02

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast CancerNCT01596751 · 2012-07-12

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)NCT01499043 · 2012-05-25

Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving MethotrexateNCT01090570 · 2010-05-01

Common conditions

Angiosarcoma1 Breast Cancer1 Breast Neoplasms1 Breast Tumors1 Early-stage Breast Cancer1 Gastrointestinal Stromal Tumor (GIST)1 HER2-negative Breast Cancer1 HER2-positive Breast Cancer1 Hormone Receptor Negative Tumor1 Hormone Receptor Positive Tumor1 Locally Advanced Breast Cancer1 Melanoma1 Metastatic Breast Cancer1 Non-small Cell Lung Cancer1 Ovarian Cancer1 Prostate Cancer1 Rheumatoid Arthritis1 Squamous Cell Carcinoma of the Head and Neck1 TNBC - Triple-Negative Breast Cancer1

Leading sponsors

Daiichi Sankyo2 Hope Rugo, MD1 Plexxikon1 QuantumLeap Healthcare Collaborative1

Trial status mix

TERMINATED2

COMPLETED1

RECRUITING1

WITHDRAWN1

Phase mix

PHASE24

PHASE13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.